A recycle content glycol ether or glycol ether ester and method of making a recycle content glycol ether or glycol ether ester wherein the recycle content is derived directly or indirectly from the cracking of recycle content pyrolysis oil and/or gas. The cracking of the pyrolysis oil can be conducted in a gas furnace or a split furnace.

A recycle content glycol ether or glycol ether ester and method of making a recycle content glycol ether or glycol ether ester wherein the recycle content is derived directly or indirectly from the cracking of recycle content pyrolysis oil and/or gas. The cracking of the pyrolysis oil can be conducted in a gas furnace or a split furnace.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 m to about 90 m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 m to about 90 m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 m to about 90 m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 m to about 90 m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

A radiation-sensitive resin composition includes: a compound A represented by formula (I); a resin B including a structural unit having an acid-dissociable group; a radiation-sensitive acid generator other than the compound A; and a solvent. R.sup.1 is an (m+m)-valent organic group and comprises a cyclopropane ring skeleton, a cyclobutane ring skeleton, or both; X.sup.1 is a group represented by formula (1-1) or a group represented by formula (1-2); X.sup.2 is a group represented by formula (2-1) or a group represented by formula (2-2); Y.sup.+ is a monovalent onium cation; m is an integer of 1 to 2, and m is an integer of 0 to 1. * represents a bond to another group.

##STR00001##

The present disclosure relates generally to methods for the preparation of Compound (I-1): I-1 or a stereoisomer or mixture of stereoisomers thereof, or salt of each thereof, as well as compounds and salts which are useful in the synthesis thereof.

##STR00001##